IRTC — iRhythm Technologies, Inc.

Summary of iRhythm Technologies, Inc. Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $192.9 million, a 31% increase year-over-year.
• Adjusted EBITDA: $21.6 million, with an adjusted EBITDA margin of 11.2%.
• Gross Margin: 71.1%, up 230 basis points from Q3 2024.
• Adjusted Net Loss: $2 million, or $0.06 per share, significantly improved from a loss of $39.2 million ($1.26 per share) in Q3 2024.
• Free Cash Flow: Positive free cash flow of $20 million for the quarter; expected to be free cash flow positive for the full year 2025 for the first time in the company's history.
• Cash Position: $565.2 million in unrestricted cash and short-term investments.

2. Strategic Updates and Business Highlights:

• Continued strong performance in both Zio Monitor and Zio AT, with record account openings and EHR integrations.
• 76 of the top 100 customers are now EHR integrated, leading to an average 25% increase in monitoring volume post-integration.
• Expansion into primary care is ongoing, with Zio being utilized as a rule-in or rule-out tool for early intervention.
• New partnerships in innovative channels are growing, with 18 active partner accounts focused on undiagnosed arrhythmias.
• Development of Zio MCT (mobile cardiac telemetry) is underway, with a 510(k) filing submitted to the FDA.
• Advancements in AI capabilities for identifying undiagnosed patients at risk of cardiac arrhythmias through partnerships, including with Lucem Health.

3. Forward Guidance and Outlook:

• Full-year 2025 revenue guidance raised to $735 million to $740 million, reflecting 24% to 25% year-over-year growth.
• Adjusted EBITDA margin guidance increased to 8.25% to 8.75%.
• Anticipation of continued strong growth in Q4, though a slight deceleration is expected due to strong Q4 2024 performance.
• Long-term gross margin target remains at 72% to 73% by 2027, with expectations for ongoing margin improvement.

4. Bad News, Challenges, or Points of Concern:

• The company is still navigating FDA remediation efforts, with communication on timelines being limited due to the FDA shutdown.
• The potential for MCT approval remains uncertain, leading to cautious guidance for 2026.
• Competitive pressures persist, particularly from traditional Holter and event monitors, which still dominate a significant portion of the market.

5. Notable Q&A Insights:

• Management highlighted that new account growth is driven by the ability to onboard entire networks quickly, enhancing customer appeal.
• The innovative partner channel is seeing varied sales cycles, with some partnerships taking over a year to scale while others are quicker.
• The potential for Zio MCT to be downgradable to an event monitor was discussed, with management noting that not much AT business is currently unreimbursed.
• The overlap between cardiac arrhythmias and sleep disorders was emphasized, with plans for future multi-sensing platform development to address both conditions.

Overall, iRhythm Technologies reported a strong quarter with significant growth and positive cash flow, while also outlining strategic initiatives and navigating challenges related to FDA approvals and market competition.